In a world marked by significant healthcare disparities and the rising burden of infectious diseases, innovation is the need of the hour. Molbio Diagnostics has redefined the landscape of molecular ...

Yuka Manabe and her team at the Center for Innovative Diagnostics for Infectious Diseases aim to improve global health with ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

Global in vitro diagnostics (IVD) market will reach $148,393.3 million by 2031, growing by 6.3% annually over 2021-2031. The global in vitro diagnostics (IVD) market encompasses a wide range of ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

The Europe In Vitro Diagnostics (IVD) market plays a crucial role in the region’s healthcare landscape, encompassing a wide range of diagnostic tests and technologies used for disease detection, ...

Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

Q1 2025 Management View CEO Steve MacMillan announced Q1 2025 revenue of $1.022 billion, reflecting a 1% increase on a constant currency basis, aligned with the company’s guidance. Non-GAAP EPS ...

The global sepsis diagnostics market is set to grow at a CAGR of 8.1%, reaching over USD 1.2 billion by 2033. Drivers include ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...